SRT2104 | GSK2245840 | CAS#1093403-33-8 | Sirtuin 1 activator

MedKoo Cat#: 205881 | Name: SRT2104

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SRT2104, also known as GSK2245840, is a novel, first-in-class, highly selective small molecule activator of the NAD + dependent deacetylase SIRT1. SRT2104 has been developed as a selective small molecule activator of SIRT1, a NAD(+)-dependent deacetylase involved in the regulation of energy homeostasis and the modulation of various metabolic pathways, including glucose metabolism, oxidative stress and lipid metabolism. SIRT1 has been suggested as putative therapeutic target in multiple age-related diseases including type 2 diabetes and dyslipidemias.

Chemical Structure

SRT2104

CAS#1093403-33-8

Theoretical Analysis

MedKoo Cat#: 205881

Name: SRT2104

CAS#: 1093403-33-8

Chemical Formula: C26H24N6O2S2

Exact Mass: 516.1402

Molecular Weight: 516.64

Elemental Analysis: C, 60.44; H, 4.68; N, 16.27; O, 6.19; S, 12.41

Price and Availability

Size	Price	Availability
5mg	USD 90.00	Ready to ship
10mg	USD 150.00	Ready to ship
25mg	USD 250.00	Ready to ship
50mg	USD 450.00	Ready to ship
100mg	USD 750.00	Ready to ship
200mg	USD 1,350.00	Ready to ship
500mg	USD 2,950.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

SRT2104; SRT 2104; SRT-2104; GSK2245840; GSK-2245840; GSK 2245840.

IUPAC/Chemical Name

4-methyl-N-(2-(3-(morpholinomethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)-2-(pyridin-3-yl)thiazole-5-carboxamide

InChi Key

LAMQVIQMVKWXOC-UHFFFAOYSA-N

InChi Code

InChI=1S/C26H24N6O2S2/c1-17-23(36-25(28-17)18-5-4-8-27-13-18)24(33)29-21-7-3-2-6-20(21)22-15-32-19(16-35-26(32)30-22)14-31-9-11-34-12-10-31/h2-8,13,15-16H,9-12,14H2,1H3,(H,29,33)

SMILES Code

O=C(C1=C(C)N=C(C2=CC=CN=C2)S1)NC3=CC=CC=C3C4=CN5C(SC=C5CN6CCOCC6)=N4

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO and DMF

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#BBC70217

QC Data

View QC data: current batch, Lot#BBC70217

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

SRT2104 is an activator of the NAD+ dependent deacetylase Sirt1, increases Sirt1 protein, but shows no effect on Sirt1 Mrna.

In vitro activity:

SRT2104 may have potential as a novel neuroprotective agent for cerebral ischemic/reperfusion injury therapy. SRT2104 inhibited neuron and microglia death directly and indirectly in oxygen glucose deprivation/reoxygenation (OGD/R)-induced cell injury models. SRT2104 treatment modulated the microglia polarization shift from the M1 phenotype and skewed toward the M2 phenotype. Additionally, SRT2104 significantly inhibited the activation of NF-κB and enhanced Sirt1 expression in microglia. Reference: Brain Res. 2021 Feb 15;1753:147236. https://pubmed.ncbi.nlm.nih.gov/33412146/

In vivo activity:

Targeting Sirtuin 1 may be a novel therapeutic strategy for Huntington's disease treatment. SRT2104 penetrated the blood-brain barrier, attenuated brain atrophy, improved motor function, and extended survival in a mouse model of Huntington's disease. Reference: Ann Clin Transl Neurol. 2014 Dec;1(12):1047-52. https://pubmed.ncbi.nlm.nih.gov/25574479/

	Solvent	mg/mL	mM
Solubility
	DMF	2.0	3.87
	DMSO	2.0	3.87

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 516.64 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Fu CY, Zhong CR, Yang YT, Zhang M, Li WA, Zhou Q, Zhang F. Sirt1 activator SRT2104 protects against oxygen-glucose deprivation/reoxygenation-induced injury via regulating microglia polarization by modulating Sirt1/NF-κB pathway. Brain Res. 2021 Feb 15;1753:147236. doi: 10.1016/j.brainres.2020.147236. Epub 2021 Jan 4. PMID: 33412146. 2. Hoffmann E, Wald J, Lavu S, Roberts J, Beaumont C, Haddad J, Elliott P, Westphal C, Jacobson E. Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man. Br J Clin Pharmacol. 2013 Jan;75(1):186-96. doi: 10.1111/j.1365-2125.2012.04340.x. PMID: 22616762; PMCID: PMC3555058. 3. Bai X, Ye D, Shi Y, Fan M, Lu P, Feng Y, Hu C, Liao J, Cui K, Tang X, Wu P, Xu F, Xu Y, Huang J. Neuroprotection of SRT2104 in Murine Ischemia/Reperfusion Injury Through the Enhancement of Sirt1-Mediated Deacetylation. Invest Ophthalmol Vis Sci. 2023 Apr 3;64(4):31. doi: 10.1167/iovs.64.4.31. PMID: 37099021; PMCID: PMC10148658. 4. Jiang M, Zheng J, Peng Q, Hou Z, Zhang J, Mori S, Ellis JL, Vlasuk GP, Fries H, Suri V, Duan W. Sirtuin 1 activator SRT2104 protects Huntington's disease mice. Ann Clin Transl Neurol. 2014 Dec;1(12):1047-52. doi: 10.1002/acn3.135. Epub 2014 Oct 31. PMID: 25574479; PMCID: PMC4284130.

In vitro protocol:

In vivo protocol:

1. Bai X, Ye D, Shi Y, Fan M, Lu P, Feng Y, Hu C, Liao J, Cui K, Tang X, Wu P, Xu F, Xu Y, Huang J. Neuroprotection of SRT2104 in Murine Ischemia/Reperfusion Injury Through the Enhancement of Sirt1-Mediated Deacetylation. Invest Ophthalmol Vis Sci. 2023 Apr 3;64(4):31. doi: 10.1167/iovs.64.4.31. PMID: 37099021; PMCID: PMC10148658. 2. Jiang M, Zheng J, Peng Q, Hou Z, Zhang J, Mori S, Ellis JL, Vlasuk GP, Fries H, Suri V, Duan W. Sirtuin 1 activator SRT2104 protects Huntington's disease mice. Ann Clin Transl Neurol. 2014 Dec;1(12):1047-52. doi: 10.1002/acn3.135. Epub 2014 Oct 31. PMID: 25574479; PMCID: PMC4284130.

1: Baksi A, Kraydashenko O, Zalevkaya A, Stets R, Elliott P, Haddad J, Hoffmann E, Vlasuk GP, Jacobson EW. A phase II, randomized, placebo-controlled, double-blind, multi-dose study of SRT2104, a SIRT1 activator, in subjects with type 2 diabetes. Br J Clin Pharmacol. 2014 Jul;78(1):69-77. doi: 10.1111/bcp.12327. PubMed PMID: 24446723; PubMed Central PMCID: PMC4168381. 2: van der Meer AJ, Scicluna BP, Moerland PD, Lin J, Jacobson EW, Vlasuk GP, van der Poll T. The Selective Sirtuin 1 Activator SRT2104 Reduces Endotoxin-Induced Cytokine Release and Coagulation Activation in Humans. Crit Care Med. 2015 Jun;43(6):e199-202. doi: 10.1097/CCM.0000000000000949. PubMed PMID: 25978169. 3: Sands BE, Joshi S, Haddad J, Freudenberg JM, Oommen DE, Hoffmann E, McCallum SW, Jacobson E. Assessing Colonic Exposure, Safety, and Clinical Activity of SRT2104, a Novel Oral SIRT1 Activator, in Patients with Mild to Moderate Ulcerative Colitis. Inflamm Bowel Dis. 2016 Mar;22(3):607-14. doi: 10.1097/MIB.0000000000000597. PubMed PMID: 26595549; PubMed Central PMCID: PMC4885523. 4: Venkatasubramanian S, Noh RM, Daga S, Langrish JP, Joshi NV, Mills NL, Hoffmann E, Jacobson EW, Vlasuk GP, Waterhouse BR, Lang NN, Newby DE. Cardiovascular effects of a novel SIRT1 activator, SRT2104, in otherwise healthy cigarette smokers. J Am Heart Assoc. 2013 Jun 14;2(3):e000042. doi: 10.1161/JAHA.113.000042. PubMed PMID: 23770971; PubMed Central PMCID: PMC3698759. 5: Hoffmann E, Wald J, Lavu S, Roberts J, Beaumont C, Haddad J, Elliott P, Westphal C, Jacobson E. Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man. Br J Clin Pharmacol. 2013 Jan;75(1):186-96. doi: 10.1111/j.1365-2125.2012.04340.x. PubMed PMID: 22616762; PubMed Central PMCID: PMC3555058. 6: Krueger JG, Suárez-Fariñas M, Cueto I, Khacherian A, Matheson R, Parish LC, Leonardi C, Shortino D, Gupta A, Haddad J, Vlasuk GP, Jacobson EW. A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis. PLoS One. 2015 Nov 10;10(11):e0142081. doi: 10.1371/journal.pone.0142081. PubMed PMID: 26556603; PubMed Central PMCID: PMC4640558. 7: Venkatasubramanian S, Noh RM, Daga S, Langrish JP, Mills NL, Waterhouse BR, Hoffmann E, Jacobson EW, Lang NN, Frier BM, Newby DE. Effects of the small molecule SIRT1 activator, SRT2104 on arterial stiffness in otherwise healthy cigarette smokers and subjects with type 2 diabetes mellitus. Open Heart. 2016 May 17;3(1):e000402. doi: 10.1136/openhrt-2016-000402. PubMed PMID: 27239324; PubMed Central PMCID: PMC4879341. 8: Libri V, Brown AP, Gambarota G, Haddad J, Shields GS, Dawes H, Pinato DJ, Hoffman E, Elliot PJ, Vlasuk GP, Jacobson E, Wilkins MR, Matthews PM. A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers. PLoS One. 2012;7(12):e51395. doi: 10.1371/journal.pone.0051395. PubMed PMID: 23284689; PubMed Central PMCID: PMC3527451. 9: Mercken EM, Mitchell SJ, Martin-Montalvo A, Minor RK, Almeida M, Gomes AP, Scheibye-Knudsen M, Palacios HH, Licata JJ, Zhang Y, Becker KG, Khraiwesh H, González-Reyes JA, Villalba JM, Baur JA, Elliott P, Westphal C, Vlasuk GP, Ellis JL, Sinclair DA, Bernier M, de Cabo R. SRT2104 extends survival of male mice on a standard diet and preserves bone and muscle mass. Aging Cell. 2014 Oct;13(5):787-96. doi: 10.1111/acel.12220. PubMed PMID: 24931715; PubMed Central PMCID: PMC4172519. 10: Jiang M, Zheng J, Peng Q, Hou Z, Zhang J, Mori S, Ellis JL, Vlasuk GP, Fries H, Suri V, Duan W. Sirtuin 1 activator SRT2104 protects Huntington's disease mice. Ann Clin Transl Neurol. 2014 Dec;1(12):1047-52. doi: 10.1002/acn3.135. PubMed PMID: 25574479; PubMed Central PMCID: PMC4284130. 11: Höppner S, Schänzer W, Thevis M. Fragmentation studies of SIRT1-activating drugs and their detection in human plasma for doping control purposes. Rapid Commun Mass Spectrom. 2013 Jan 15;27(1):35-50. doi: 10.1002/rcm.6421. PubMed PMID: 23239315. 12: Höppner S, Delahaut P, Schänzer W, Thevis M. Mass spectrometric studies on the in vivo metabolism and excretion of SIRT1 activating drugs in rat urine, dried blood spots, and plasma samples for doping control purposes. J Pharm Biomed Anal. 2014 Jan;88:649-59. doi: 10.1016/j.jpba.2013.10.022. PubMed PMID: 24239904. 13: Höppner S, Schänzer W, Thevis M. Mass spectrometric studies on the in vitro generated metabolites of SIRT1 activating drugs for doping control purposes. J Mass Spectrom. 2013 Jul;48(7):830-43. doi: 10.1002/jms.3227. PubMed PMID: 23832939. 14: Kim HN, Han L, Iyer S, de Cabo R, Zhao H, O'Brien CA, Manolagas SC, Almeida M. Sirtuin1 Suppresses Osteoclastogenesis by Deacetylating FoxOs. Mol Endocrinol. 2015 Oct;29(10):1498-509. doi: 10.1210/me.2015-1133. PubMed PMID: 26287518; PubMed Central PMCID: PMC4588729. 15: Thevis M, Kuuranne T, Walpurgis K, Geyer H, Schänzer W. Annual banned-substance review: analytical approaches in human sports drug testing. Drug Test Anal. 2016 Jan;8(1):7-29. doi: 10.1002/dta.1928. Review. PubMed PMID: 26767774. 16: Bonkowski MS, Sinclair DA. Slowing ageing by design: the rise of NAD(+) and sirtuin-activating compounds. Nat Rev Mol Cell Biol. 2016 Nov;17(11):679-690. doi: 10.1038/nrm.2016.93. PubMed PMID: 27552971; PubMed Central PMCID: PMC5107309. 17: Thevis M, Schänzer W. Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis - Potential implications for sports drug testing programs. Rapid Commun Mass Spectrom. 2016 Mar 15;30(5):635-51. doi: 10.1002/rcm.7470. PubMed PMID: 26842585. 18: Villalba JM, Alcaín FJ. Sirtuin activators and inhibitors. Biofactors. 2012 Sep-Oct;38(5):349-59. doi: 10.1002/biof.1032. Review. PubMed PMID: 22730114; PubMed Central PMCID: PMC3467333. 19: Camins A, Sureda FX, Junyent F, Verdaguer E, Folch J, Pelegri C, Vilaplana J, Beas-Zarate C, Pallàs M. Sirtuin activators: designing molecules to extend life span. Biochim Biophys Acta. 2010 Oct-Dec;1799(10-12):740-9. doi: 10.1016/j.bbagrm.2010.06.005. Review. PubMed PMID: 20601277.